Skip Navigation

Cardiovascular Research 2004 64(2):243-249; doi:10.1016/j.cardiores.2004.07.002
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mehta, J.L.
Right arrow Articles by Li, D.Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, J.L.
Right arrow Articles by Li, D.Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells

J.L. Mehta*, J. Chen, F. Yu and D.Y. Li

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and the Central Arkansas Veterans Healthcare System, 4301 West Markham St., #532, Little Rock, AR 72205-7199, United States

* Corresponding author. Tel.: +1 501 296 1401; fax: +1 501 686 6180. Email address: MehtaJL{at}uams.edu

Background: Aspirin is thought to exert salutary effects in vascular disease states by inhibiting platelet aggregation. Endothelial activation, accumulation of oxidized low-density lipoprotein (ox-LDL) and intense inflammation also characterize atherosclerotic plaque in acute myocardial ischemia. Ox-LDL induces expression of lectin-like receptors (LOX-1) on endothelial cells and leads to the expression of matrix metalloproteinases (MMPs), which destabilize the atherosclerotic plaque. We hypothesized that aspirin may interfere with LOX-1 expression and subsequent MMP activation.

Methods and results: Cultured human coronary artery endothelial cells (HCAECs) were incubated with aspirin (1–5 mM), sodium salicylate (5 mM) or the cyclo-oxygenase inhibitor indomethacin (0.25 mM) before treatment with ox-LDL. Aspirin, in a dose- and time-dependent fashion, reduced ox-LDL-mediated LOX-1 expression (P<0.01). Ox-LDL also increased MMP-1 expression and activity, and treatment of HCAECs with aspirin decreased this effect (P<0.01). Ox-LDL also enhanced the activity of p38MAPK in HCAECs, and aspirin blocked this effect of ox-LDL (P<0.01). Treatment of HCAECs with salicylate, but not indomethacin, resulted in a suppression of LOX-1 expression, an effect similar to that of aspirin. Importantly, both aspirin and salicylate, but not indomethacin, decreased superoxide anion generation in ox-LDL-treated HCAECs (P<0.05).

Conclusion: These observations suggest that aspirin inhibits ox-LDL-mediated LOX-1 expression and interferes with the effects of ox-LDL in intracellular signaling (p38MAPK activation) and subsequent MMP-1 activity. These novel effects of aspirin may complement its platelet inhibitory effect in acute myocardial ischemia.

KEYWORDS Aspirin; Endothelial cells; Lectin-like ox-LDL receptor (LOX-1); MAP kinase; Metalloproteinases; Oxidation


Time for primary review 11 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
A. M. Vincent, J. M. Hayes, L. L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E. L. Feldman
Dyslipidemia-Induced Neuropathy in Mice: The Role of oxLDL/LOX-1
Diabetes, October 1, 2009; 58(10): 2376 - 2385.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Dandapat, C. Hu, L. Sun, and J. L. Mehta
Small Concentrations of oxLDL Induce Capillary Tube Formation From Endothelial Cells via LOX-1 Dependent Redox-Sensitive Pathway
Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2435 - 2442.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. R. Marwali, C.-P. Hu, B. Mohandas, A. Dandapat, P. Deonikar, J. Chen, I. Cawich, T. Sawamura, M. Kavdia, and J. L. Mehta
Modulation of ADP-Induced Platelet Activation by Aspirin and Pravastatin: Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Nitric Oxide, Oxidative Stress, and Inside-Out Integrin Signaling
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1324 - 1332.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. L. Mehta, N. Sanada, C. P. Hu, J. Chen, A. Dandapat, F. Sugawara, H. Satoh, K. Inoue, Y. Kawase, K.-i. Jishage, et al.
Deletion of LOX-1 Reduces Atherogenesis in LDLR Knockout Mice Fed High Cholesterol Diet
Circ. Res., June 8, 2007; 100(11): 1634 - 1642.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. P. Brandes
Roads to Dysfunction: Argininase II Contributes to Oxidized Low-Density Lipoprotein-Induced Attenuation of Endothelial NO Production
Circ. Res., October 27, 2006; 99(9): 918 - 920.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Chen and J. L. Mehta
Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1738 - H1745.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. L. Mehta, J. Chen, P. L. Hermonat, F. Romeo, and G. Novelli
Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders
Cardiovasc Res, January 1, 2006; 69(1): 36 - 45.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. Kojda
Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?
Cardiovasc Res, November 1, 2004; 64(2): 192 - 194.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.